Research programme: gene therapy - 4D Molecular Therapeutics/Foundation Fighting Blindness

Drug Profile

Research programme: gene therapy - 4D Molecular Therapeutics/Foundation Fighting Blindness

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 4D Molecular Therapeutics
  • Developer 4D Molecular Therapeutics; Foundation Fighting Blindness
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Retinal disorders

Most Recent Events

  • 24 Jul 2017 Early research in Retinal disorders in USA (Intravitreous)
  • 24 Jul 2017 4D Molecular Therapeutics and Foundation Fighting Blindness enters into collaboration to develop AAV-based gene therapy in USA for Retinal diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top